NASDAQ:ATOS Atossa Genetics (ATOS) Stock Price, News & Analysis $2.39 -0.05 (-2.05%) Closing price 10/12/2026 03:59 PM EasternExtended Trading$2.40 +0.01 (+0.63%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Atossa Genetics Stock (NASDAQ:ATOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atossa Genetics alerts:Sign Up Key Stats Today's Range$2.34▼$2.5350-Day Range$1.90▼$2.7952-Week Range$1.70▼$17.25Volume81,418 shsAverage Volume76,617 shsMarket Capitalization$23.85 millionP/E RatioN/ADividend YieldN/APrice Target$20.33Consensus RatingModerate Buy Company Overview Atossa Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer. The company’s research is centered on precision medicines intended to address unmet needs in breast cancer treatment and prevention. Atossa’s leading development program is oral endoxifen, an active metabolite of tamoxifen and a selective estrogen receptor modulator. The company is evaluating endoxifen in clinical studies involving hormone receptor-positive breast cancer, including settings before surgery and in patients who may benefit from reducing tumor activity or breast cancer risk. Founded in 2009 and headquartered in Seattle, Washington, Atossa initially pursued diagnostic products for breast health before concentrating its business on therapeutic development. The company serves the global biopharmaceutical and medical research markets through its clinical programs and collaborations. Steven Quay, M.D., Ph.D., is the company’s founder and chief executive officer.AI Generated. May Contain Errors. Read More Atossa Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreATOS MarketRank™: Atossa Genetics scored higher than 43% of companies evaluated by MarketBeat, and ranked 636th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingAtossa Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAtossa Genetics has a consensus price target of $20.33, representing about 750.8% upside from its current price of $2.39.Amount of Analyst CoverageAtossa Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Atossa Genetics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atossa Genetics are expected to grow in the coming year, from ($3.75) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Genetics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Genetics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Genetics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atossa Genetics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.76% of the float of Atossa Genetics has been sold short.Short Interest Ratio / Days to CoverAtossa Genetics has a short interest ratio ("days to cover") of 11.31, which indicates bearish sentiment.Change versus previous monthShort interest in Atossa Genetics has recently increased by 3.43%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtossa Genetics does not currently pay a dividend.Dividend GrowthAtossa Genetics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.82 News SentimentAtossa Genetics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atossa Genetics this week, compared to 3 articles on an average week.Search Interest7 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows3 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atossa Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders9.80% of the stock of Atossa Genetics is held by insiders.Percentage Held by Institutions12.74% of the stock of Atossa Genetics is held by institutions.Read more about Atossa Genetics' insider trading history. Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATOS Stock News HeadlinesAtossa (NASDAQ: ATOS) ties PRV payout to 25% of voucher proceeds under CVR dealOctober 12 at 3:02 AM | americanbankingnews.comAtossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValueOctober 9, 2026 | prnewswire.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 13 at 1:00 AM | Reagan Gold Group (Ad)Q3 EPS Forecast for Atossa Genetics Raised by AnalystOctober 6, 2026 | americanbankingnews.comAtossa plans CVR with $50 million capOctober 2, 2026 | americanbankingnews.comAtossa plans shareholder stake in potential PRV proceedsSeptember 30, 2026 | msn.comAtossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review VoucherSeptember 29, 2026 | prnewswire.comAtossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of AgingSeptember 24, 2026 | prnewswire.comSee More Headlines ATOS Stock Analysis - Frequently Asked Questions How have ATOS shares performed this year? Atossa Genetics' stock was trading at $8.85 at the beginning of 2026. Since then, ATOS shares have decreased by 73.0% and is now trading at $2.39. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc. (NASDAQ:ATOS) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.07. When did Atossa Genetics' stock split? Shares of Atossa Genetics reverse split on Monday, February 2nd 2026.The 1-15 reverse split was announced on Monday, January 26th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 30th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Atossa Genetics IPO? Atossa Genetics (ATOS) raised $6 million in an initial public offering on Thursday, November 8th 2012. The company issued 1,200,000 shares at $4.00-$6.00 per share. How do I buy shares of Atossa Genetics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atossa Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Genetics investors own include Zomedica (ZOM), AUO (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK) and The RMR Group (RMR). Company Calendar Last Earnings8/07/2026Today10/13/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ATOS's financial health is in the Red zone, according to TradeSmith. ATOS has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATOS CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees14Year Founded2009Price Target and Rating Average Price Target for Atossa Genetics$20.33 High Price Target$25.00 Low Price Target$12.00 Potential Upside/Downside+750.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-102.99% Return on Assets-85.78% Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.57 per share Price / Book0.52Miscellaneous Outstanding Shares9,980,000Free Float9,001,000Market Cap$23.85 million OptionableOptionable Beta1.27 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ATOS) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
